Merrill JT, et al. - The purpose of this trial was to inspect the efficacy and safety of atacicept, an antagonist of BLyS/APRIL-mediated B cell activation, in patients with systemic lupus erythematosus (SLE). The efficacy of atacicept was illustrated in this study, especially among high disease activity (HDA) and serologically active disease (SA) patients. Therapy with atacicept led to reductions in disease activity and severe flare. An acceptable safety profile was brought to light with this treatment.